After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B. The company announced the great news after the market closed on Thursday. Dynavax stock jumped on …
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are trading lower by $1.95 (8 percent ... Dynavax has been a "sell the news" scenario as the stock has nearly doubled since its July 27 low of $8.90 when it reached $24.45 on …
Below is a chart showing ADI's trailing twelve month trading history, with the $82.50 strike highlighted in orange: And Dynavax Technologies Corp (DVAX) saw options trading volume of 6,824 contracts, representing approximately …
based Dynavax's shares (NASDAQ:DVAX) closed Friday at $20.25 ... Dynavax …
In reaction to the news, the analyst maintains an Outperform rating on DVAX stock with a price target of $30, which …
The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 271,093 shares traded. …
That means there’s plenty of reward left even after today’s gains, especially if Heplisav gets FDA-approval. Just remember: The biotech space is highly volatile, and that’s reflected in the DVAX stock price in 2016.
Investors in Dynavax Technologies Corporation DVAX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $15 Put had some of the highest implied volatility of all equity …
Dynavax Technologies (DVAX) also has suffered following the Food and Drug Administration's approval of its drug dubbed Heplisav-B to treat hepatitis B. The …
On September 2, DVAX fell over 32% after the FDA canceled the advisory committee meeting for November, saying it needed time to review and resolve several outstanding issues. On October 3, DVAX disclosed that it had received the …